Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 7/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26033464 | 0.84 | HRH3 (0.52) | TAAR1ACMSDLOXL2 | |
| SCHEMBL10793933 | 0.81 | ACMSD (0.53) | ALDH1A1ACMSDKMT2ATDP1 | |
| SCHEMBL18905499 | 0.81 | ACMSD (0.41) | ACMSDKMT2ATDP1 | |
| SCHEMBL2643410 | 0.79 | ACMSD (0.46) | TAAR1ALDH1A1ACMSDKMT2ATDP1 | |
| SCHEMBL18905430 | 0.78 | ACMSD (0.40) | ALDH1A1ACMSDKMT2ATDP1 | |
| SCHEMBL34460174 | 0.78 | ACMSD (0.45) | ALDH1A1BACE1ACMSDKMT2ATDP1 | |
| SCHEMBL18905445 | 0.77 | ACMSD (0.39) | ACMSDKMT2A | |
| SCHEMBL8885877 | 0.76 | ACMSD (0.44) | ALDH1A1ACMSDKMT2ATDP1 | |
| SCHEMBL11862219 | 0.76 | ACMSD (0.47) | ACMSDKMT2ATDP1 | |
| SCHEMBL18724371 | 0.76 | ACMSD (0.44) | ACMSDKMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957507-B1 | ANTIBACTERIAL 4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS HAVING MULTIPLE SUBSTITUENTS | IONIS PHARMACEUTICALS INC (US) | 2018-10-24 | — | — | EP | disclosed |
| US-8569264-B2 | Antibacterial 4,5-substituted aminoglycoside analogs having multiple substituents | ISIS PHARMACEUTICALS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20130005674-A1 | ANTIBACTERIAL 4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS HAVING MULTIPLE SUBSTITUENTS | ISIS PHARMACEUTICALS, INC. (US) | 2013-01-03 | — | — | US | disclosed |
| US-8114856-B2 | Antibacterial 4,5-substituted aminoglycoside analogs having multiple substituents | ISIS PHARMACEUTICALS, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20110166334-A1 | ANTIBACTERIAL 4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS HAVING MULTIPLE SUBSTITUENTS | ISIS PHARMACEUTICALS,INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-7893039-B2 | Antibacterial 4,5-substituted aminoglycoside analogs having multiple substituents | ISIS PHARMACEUTICALS, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20080293649-A1 | ANTIBACTERIAL 4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS HAVING MULTIPLE SUBSTITUENTS | ISIS PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| EP-1957507-A2 | ANTIBACTERIAL 4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS HAVING MULTIPLE SUBSTITUENTS | Isis Pharmaceuticals, Inc. (US) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007064954-A2 | ANTIBACTERIAL 4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS HAVING MULTIPLE SUBSTITUENTS | ISIS PHARMACEUTICALS, INC. (US) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166334-A1 | ANTIBACTERIAL 4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS HAVING MULTIPLE SUBSTITUENTS | ALG8, MRPL21, AADAC | MAOB 2925/4885TAAR1 4813/4885CYP2A6 1438/4885 |
| US-20080293649-A1 | ANTIBACTERIAL 4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS HAVING MULTIPLE SUBSTITUENTS | ALG8, MRPL21, AADAC | MAOB 2925/4885TAAR1 4813/4885CYP2A6 1438/4885 |
| US-20130005674-A1 | ANTIBACTERIAL 4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS HAVING MULTIPLE SUBSTITUENTS | ALG8, MRPL21, AADAC | MAOB 2925/4885TAAR1 4813/4885CYP2A6 1438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.